Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

MindMed begins phase I study of DMT

July 30, 2021

180 Life Sciences selects lead synthetic CBD analogue for inflammation and pain

July 30, 2021

Restoring chondroitin 6-sulfate can rescue age-related memory impairment

July 29, 2021

ISIS-814907 well tolerated in first-in-human study in mild Alzheimer's disease patients

July 29, 2021

Chengdu Baiyu Pharmaceutical presents new tetrahydrocannabinol derivatives

July 29, 2021

Grunenthal begins phase I trial of glucocorticoid receptor modulator

July 27, 2021

First-in-human safety and PK data reported for pirepemat

July 27, 2021

Enrollment opens in phase I study of BI-1569912 for major depressive disorder

July 27, 2021

XWPharma starts first-in-human study of XW-10508

July 27, 2021

Japan Tobacco divulges new NLRP3 inflammasome inhibitors

July 27, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...